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patients using CSII and CGM; and 5)Results are more sensitive to reimbursement for 
routine physician care and lifestyle modification services. ConClusions: 1) Seven 
American professional societies comprising the Diabetes Working Group (DWG) 
concur delivering high-quality, guideline-based diabetes care unrealistic given cur-
rent care and payment paradigms; 2) DWG recommends alternative approaches 
in 3 areas: care management, payment reform, and workforce supply, to mitigate 
increasing medical and financial impact of this epidemic chronic illness; 3) Model 
can be used internationally to support public policy efforts.
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1IMS Health, Alexandria, VA, USA, 2Eli Lilly and Company, Windlesham, Surrey, UK
objeCtives: Evaluate treatment patterns of Type 2 diabetes (T2D) patients initiat-
ing glucagon-like peptide-1 receptor agonists (GLP1) or insulin glargine in Germany 
(GE) and UK. Methods: Adult T2D patients initiating exenatide twice-daily (exBID), 
liraglutide (LIRA) or glargine (1/10-12/11), or exenatide once-weekly (exQW) (1/10-
6/12), were identified using the IMS LifeLink™ EMR-EU databases (exQW in GE 
only). Therapy initiation date was termed ‘index date’. Eligible patients were naïve 
to index therapy class and had ≥ 180 days pre- and ≥ 360 days post-index data (180 
post-index exQW only). Treatment modification was evaluated over 180-day and 
total post-index period. Patients were required to have non-missing prescription 
data. Results: 6,171 GE (300 exBID/174 exQW/906 LIRA/4,791 glargine) and 1,042 UK 
(249 exBID/306 LIRA/487 glargine) patients were included. Approximately half were 
male (GE/UK% 53.9/51.9). At index, mean age in GE/UK was 57.6/57.6 among GLP1 
initiators; 67.4/63.1 among glargine initiators. Incidence of treatment modification 
(discontinuation, switch or augmentation) over 180-day post-index varied by treat-
ment and country (GE/UK,%): exBID (58.0/41.4), LIRA (54.1/39.2), exQW (40.8/NA), 
glargine (13.7/29.2). Augmentation as first modification was rare among exBID and 
LIRA patients (GE/UK,% of those with modification); 11.5/6.8 and 10.0/7.5, respec-
tively, compared to exQW (26.8/NA) and glargine (66.1/45.1). Discontinuation rates 
(i.e., stopping index therapy without switch to a new therapy) were higher than 
switching rates throughout the 180-day period for GLP1 and glargine users (GE/UK,% 
of those with modification): GLP1 74.4/75.3 discontinuation & 13.6/17.5 switch; glar-
gine 32.9/52.8 discontinuation and 1.1/2.1 switch. Using all available post-index data, 
mean follow-up was (GE/UK, months): exBID 24.5/25.6, LIRA 24.0/21.8, exQW 10.6/
NA, and glargine 24.4/25.4; proportions with treatment modification were (GE/UK,%): 
exBID 91.0/81.5, LIRA 80.1/71.6, exQW 57.5/NA, glargine 69.8/72.1. ConClusions: 
Treatment patterns varied among GLP1 and glargine patients. Longer-term data 
would be useful to further elucidate practice patterns associated with these medi-
cines, particularly exQW.
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objeCtives: The United Arab Emirates (UAE) has among the highest prevalence 
(25%) of type 2 diabetes mellitus (T2DM) globally; however, few data are available 
on how patients are managed in clinical practice. The objective was to characterize 
recent treatment patterns among T2DM patients in Dubai. Methods: Charts from 
T2DM patients aged ≥ 18 years that visited the Dubai Hospital between October 
2009 and March 2010 (enrolment period) were systematically sampled until the tar-
get (n= 250) was reached. Treatment data from enrolment to September 2011 were 
abstracted from patient charts, as well as treatments received before enrolment. 
Treatment regimens, their frequency of use, and the number of switches (drug 
replacement/removal/addition) over the study period were calculated. Analyses 
were stratified by T2DM duration, and data for those recently-diagnosed (< 5 years; 
n= 29) and with longstanding disease (≥ 20 years; n= 67) are presented. Results: 
Mean age at enrolment was 58 years (SD: 12 years), 33% were male, and mean 
T2DM duration was 14 years (SD: 8 years). At enrolment, 74% of patients had 
received prior insulin treatment (recently-diagnosed: 55%; longstanding disease: 
84%). During the study period, the most common regimens were insulin+oral 
combination therapy (55%) and oral combination therapy (39%). Overall, 67% 
received any insulin therapy during the study period (recently-diagnosed: 45%; 
longstanding disease: 87%). By study end, 78% had received insulin therapy at 
any time (recently-diagnosed: 62%; longstanding disease: 88%). On average, T2DM 
patients had two treatment switches; little variation was seen by T2DM dura-
tion. ConClusions: Most patients had longstanding T2DM and received treat-
ment with insulin. Patients had an average of two treatment switches over the 
relatively short study period, indicating modification was attempted to improve 
T2DM control. Novel therapies may improve clinical outcomes among T2DM 
patients and this study provides valuable baseline data with which to compare 
the effectiveness of new T2DM treatments in Dubai.
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The increasing budgetary constraints faced by health care payers have made the 
access decision increasingly complex and decentralized processes a growing trend. 
Thus, demonstration of new health technologies value has become critical to ensure 
patients’ access to innovation.objeCtives: To identify the most important value 
messages within decision making process in the treatment of Type 2 Diabetes 
Mellitus (T2DM) among General Practitioners (GP) coordinating Primary Care 
Centers. Methods: Regional meetings based on Health Economics training held 
(during 2013) with GPs, including the presentation of a cost-effectiveness analysis of 
vildagliptin vs sulphonilureas (SU) and a budget impact tool that enables the estima-
tion of meaningful impacts of T2DM. Two surveys were developed to be applied at 
beginning and end of training to characterize the learning insights and identify the 
factors considered in the decision process. Results: Partial results based on a 51 
GPs sample are presented. The positive impact of the training in HE concepts was 
statistically significant (p= 0.000) with an 89.4% average rate of correct answers. More 
than 50% of GPs considered the increasing prevalence of T2DM, cost of macrovascu-
lar and microvascular complications and the impact of hipoglycaemias in patients’ 
quality of life (QoL) and costs, as the most important factors in the decision process. 
The key decision factor to use vildagliptin is the improvement of patients’ QoL. The 
use of SU is explained due to its fast response, mainly in patients with Hb1Ac level 
above 7.5%. Majority of GPs (87.5%) chose vildagliptin as the preferred therapeutic 
for T2DM patients not controlled with metformin. ConClusions: This analysis 
demonstrated that both epidemiological and economic factors are important at 
local decision process. Clinically, patients’ QoL is the most relevant achievement. 
Most GPs prefer vildagliptin to control T2DM, considering QoL improvements its 
greatest benefit.
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objeCtives: Despite the high prevalence (25%) of type 2 diabetes mellitus (T2DM) in 
the United Arab Emirates (UAE), few data are available on the types and quality of care 
administered. Quality of care is an important determinant of whether clinical targets 
can be met, and serious complications avoided. The objective was to estimate the 
proportion of T2DM patients receiving recommended monitoring of clinical measures 
in Dubai, over one year. Methods: Charts from T2DM patients aged ≥ 18 years that 
visited the Dubai Hospital between October 2009 and March 2010 (enrolment period) 
were systematically sampled until the target (n= 250) was reached. Quality of care 
was assessed from April 2010 to March 2011, adapted from the United States (US) 
Healthcare Effectiveness Data and Information Set (HEDIS) Comprehensive Diabetes 
Care measures. Measures included: glycosylated haemoglobin (HbA1c) screening, 
control (< 8%) and poor control (> 9%); low-density lipoprotein (LDL) screening and 
control (< 100mg/dL); blood pressure (BP) control (< 140/90mmHg); retinopathy screen-
ing; and medical attention for nephropathy. Patients were classified as having control 
based on their latest test in the period. Results: Mean age at enrolment was 58 years 
(standard deviation (SD): 12 years), 33% were male, and mean T2DM duration was 14 
years (SD: 8 years). Over the 12-month period, 98% underwent HbA1c screening (54% 
had control and 26% displayed poor control); 90% underwent LDL screening (64% 
had control); 43% had BP control; 32% had retinopathy screening; and 16% attention 
for nephropathy. Two-hundred and eleven patients (84%) were screened for BP, LDL 
and HbA1c measures over the period. ConClusions: Guideline monitoring was 
conducted for most patients; rates of compliance were comparable to or higher than 
US benchmarks for HbA1c and LDL monitoring. Greater understanding of the factors 
leading to high adherence to the guidelines would be useful for other areas of preven-
tive care, and other hospitals and jurisdictions.
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usInG a “sTanDarDs of Care eConomIC moDeL” To QuanTIfy BarrIers 
anD PoTenTIaL soLuTIons To ProVIDInG oPTImaL GuIDeLIne-DrIVen 
Care To PaTIenTs wITH DIaBeTes meLLITus In THe unITeD sTaTes
Hughes K.E.
Avalere Health LLC, Washington, DC, USA
objeCtives: 1) Build economic model to estimate resources to deliver current 
standards of care to US diabetes patients, and 2) Evaluate provider costs to meet 
standards, assess patient outcomes specified in guidelines relative to reimburse-
ment. Methods: Build model: 1) Integrate 3 national standard sets (ADA, AACE, 
and TES) into 28 consolidated standards of optimal care; 2) Develop provider matrix 
for rendering care; 3) Draft 6 clinical vignettes: 3 each T1DM and T2DM; 4) Convene 
3 multidisciplinary panels of 4-7 care professionals; with facilitator, estimate mini-
mum/maximum time to achieve care standards/patient type – baseline/best cases; 
5) Convene separate panel estimating time to start/follow patients using CSII or 
CGM; 6) Multiply provider time by average wage and overhead amounts to deter-
mine visit cost; 7) Map activities to CPT and HCPCS billing codes and payment 
rates; 8) Compute reimbursement per expected payer mix; and 9) Note gaps in 
reimbursement compared to costs on unit and total basis. Populate model; perform 
analytics: Repeat Steps 4-9 with data from national provider survey and national 
database. Results: 1) Baseline scenarios show provider costs exceed reimburse-
ments for all type patients; best case indicates same in 5 of 6 scenarios; 2) In dif-
ferent scenarios costs of treating adults exceed reimbursement by > $750,000 per 
year; practices would require 19%-64% increase to breakeven; 3) In pediatric prac-
tice, costs exceed reimbursement by > $471,000 per year; 4) Gaps are increased for 
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THe roLe of CommunICaTIon anD HeaLTH LITeraCy on PaTIenT safeTy 
In PuBLIC PHarmaCIes In THe rePuBLIC of srPska
Janjic Z.1, Tasic L.2, Rados L.3, Krajnovic D.2, Medic G.4
1Pharmacies “Zdravlje Pharm”, Bijeljina, Republic of Srpska, Bosnia, 2University of Belgrade – 
Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 3Pharmacy Zrenjanin, Zrenjanin, Serbia 
and Montenegro, 4Mapi - HEOR & Strategic Market Access, 3995 AX Houten, The Netherlands
Health literacy is the skill (social and cognitive) that determines the motivation 
and ability of the person to receive, understand and use information in order 
to improve and maintain good health. Communication between patients and 
pharmacist is essential for optimal patient safety.objeCtives: To highlight the 
importance and present the results of conducted research and to give recom-
mendations for improving the health literacy among patients and pharmacists’ 
communication skills. Methods: The study was conducted in June 2013 in 5 
selected branches of pharmacy-chain “Zdravlje Pharm” in Bijeljina, Republic of 
Srpska, Bosnia and Herzegovina. The sample consisted of 219 patients selected 
randomly, of whom 195 accepted the survey, and 24 rejected to participate. The 
instrument was previously validated and adjusted questionnaire of Pharmacy 
Zrenjanin, Serbia, related to patient satisfaction with pharmacy services, but 
also conceived needs of the thesis, with 32 close-type questions, except one. 
Health literacy of patients and communication with pharmacists were fol-
lowed. The analysis was done in Excel, and the results are given in tables and 
graphs. Results: About 90% of patients reported that pharmacists give clear 
information during consultations and the advices helped them. A total of 65% 
reported to easily remember the information from the pharmacists, which shows 
a good level of patient health literacy; but the rest can have uncertain outcomes 
of the therapy and be exposed to greater safety risks. ConClusions: There is a 
place for improvement of aspects which can contribute to better patient safety. 
That can be achieved by applying certification standards throughout the health 
care system in the Republic of Srpska.
PHP5
are THe BIoTeCHnoLoGy anD PHarmaCeuTICaL seCTors DefensIVe 
reLaTIVe To THe s&P 500?
Furnback W., Wang B., Magyar A.F.
Alliance Life Sciences, Somerset, NJ, USA
objeCtives: The health care sector is widely regarded as a defensive play in the 
stock market. We analyzed the performance of a pharmaceutical and a biotechnol-
ogy index from March 2000 through April 2013 alongside the S&P 500. Methods: 
We categorized the S&P 500 from March 2000 through April 2013 into bull and bear 
markets. During this time there were three bull markets and three bear markets. 
Bull and bear markets were defined as changes in the S&P 500 of more than 20%. 
We followed the AMEX Pharmaceutical (^DRG) and Biotechnology (^BTK) Indices to 
represent their sectors. We compared the returns of the sectors with the overall mar-
ket and also calculated their correlated volatility (beta) with the S&P 500. Results: 
For the entire analysis period, the S&P 500 returned 4.59% while ^DRG and ^BTK 
returned 25.43% and 252.83%, respectively. During the bear markets, the S&P 500 
lost at an average annual rate of 27.17%, while ^DRG and ^BTK lost at annual rates 
of 12.16% and 21.99%, respectively. Though ^DRG performed best during the bear 
markets, it was a laggard in the bull market gaining 8.15% annually, while the S&P 
500 and ^ BTK had 22.04% and 31.97% annual returns, respectively. The overall beta 
during our analysis period was 0.63 for ^DRG and 1.07 for ^BTK. ConClusions: 
Both the AMEX Pharmaceutical and Biotechnology Indices fell at a lesser rate than 
the S&P 500 during bear markets. The Pharmaceutical Index may be the more defen-
sive play as it lost at an average annual rate of more than two times less than the 
S&P 500. However, the Biotechnology Index gained almost four times more than the 
Pharmaceutical Index in bull markets and also outperformed the S&P 500 by almost 
10 percentage points during bull markets.
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objeCtives: Diagnosis Related Groups (DRG) based methods was introduced for 
acute hospital care reimbursement in 1993 in Hungary (H-DRG) and in 2003 in 
Germany (G-DRG). The aim of our study is to compare the development of DRG 
base rate in Germany and Hungary. Methods: The Hungarian data derive from the 
financial database of the Hungarian National Health Insurance Fund Administration 
(NHIFA), the only health care financing agency in Hungary. German data derive 
from German DRG Institute. We analyzed how the uniform, nationwide DRG base 
rate has been introduced in both countries. Results: The German DRG system 
consists of 1200 disease groups, while the Hungarian contains ca. 736 groups. The 
German DRG base rate was hospital specific between 2003-2004. From 2005 to 2009 
hospital-specific base rates converged to a state-wide base rate. From 2010 to 2014, 
the state-wide base rates should converge to a nationwide base rate. The German 
hospital specific base rate varied between EUR2200-3200. In Hungary, a hospital 
groups specific base rate was applied for 16 groups of hospitals between 1993-
1998 with a gradual converge of base rates. Middle level (county or regional) base 
rate was not introduced in Hungary. The nationwide uniform DRG base rate was 
set up in 1998 in Hungary. The Hungarian uniform DRG base rate was EUR518 in 
2012. ConClusions: Both Hungary and Germany applied a gradual implementa-
tion of uniform DRG base rate. Germany took three steps (hospital, Lander and 
nationwide), while Hungary took two steps (hospital group, nationwide) in reaching 
the nationwide uniform DRG base rate.
objeCtives: Turkish health care system has developed in terms of quality, access, 
equity and efficiency with the introduction of a number of reforms under “Health 
Transformation Program” since 2003. However, these have created significant 
financial burden to the government. In order to contain expenditures, avoid over-
use, misuse and abuse; government has implemented certain cost sharing tools. 
Our objective is to define how co-payment mechanism has affected patients’ 
purchasing behavior regarding OTC-type products. Methods: Regulations and 
reports published by Ministry of Health and Social Security Institution, “Health 
Systems in Transition Turkey 2011” and “IMS Market Prognosis 2012-2016” reports 
are examined. Results: In Turkey, family physicians do not act like gatekeepers 
since a formal referral system does not exist. Therefore, patients could directly 
apply to secondary/tertiary health care services without co-pay. At secondary/
tertiary health care levels, co-payment rate is 5 TL and 12 TL for outpatient care 
in public and private hospitals respectively, 3 TL for prescription fee and extra 
1 TL for each product exceeding 3 products per prescription. All active workers 
pay 20% while retirees pay 10% of total amount of the prescriptions as co-pay. 
Patients with chronic conditions requiring medical report are exempt from co-
pay. Considering different co-payment rates and number of visits/prescriptions 
recorded in hospitals, it is calculated that patients paid approximately 3 billion 
TL in total outpatient care as co-payment in 2012. ConClusions: Minimum 9 
TL in total is required as a co-payment for outpatient care and prescription, if 
patient visits a public hospital. Therefore, for products with a lower price than 
10 TL, patients rather go directly to pharmacies. This behavioral change of out-
of-pocket payments might be explained by improved purchasing power and 
increased co-pay rates.
PHP2
meTHoDoLoGICaL CHaLLenGes In muLTI-CrITerIa DeCIsIon anaLysIs 
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objeCtives: Decision making about health technologies from research and 
development to reimbursement is affected by heterogeneous opinion and cri-
teria of participating stakeholders. There is a lack of systematic consideration 
of stakeholders’ preferences in current health policy. Multi-criteria decision 
analysis (MCDA) offers a solution to take preferences into account. This study 
gives an overview about the applications of MCDA methods in health economic 
decision-making. Methods: A systematic review of the health care literature 
was performed to identify original research articles. Using predefined categories, 
data was systematically extracted for the type of policy applications, MCDA 
methodology, criteria used and how they were defined. Results: Twenty-one 
studies were included in the analysis. 12 studies (67%) used indirect approaches 
and nine studies (43%) used direct MCDA approaches. Four studies (19%) focused 
on technologies in the early innovation process. The majority of 17 studies (81%) 
examined a technology on the level of reimbursement decision. Eight studies 
(38%) resulted into implementation, which means that an official committee 
considered the MCDA results. Other studies were conducted in an explorative 
manner. MCDA decision criteria used were obtained from literature research and 
context-specific studies, expert opinions, and group discussions. The number of 
criteria ranged from three up to 15. The most prominent criteria described health 
outcomes (71%), disease impact (62%), and implementation of the intervention 
(38%). ConClusions: MCDA is used at different levels of medical innovation 
and can increase transparency for involved stakeholders by explicitly structuring 
decision criteria. Further research is needed to understand existing variability 
of the number of criteria used and ensure that models are robust regarding 
potential criteria overlaps, performance scales and operationalizability aligned 
with evidence needs.
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suPPLemenTary HeaLTH InsuranCe In Turkey
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objeCtives: In Turkey, almost everyone is covered by General Health Insurance 
Scheme (GHIS) under Social Security Institution (SSI). GHIS provides a Basic 
Benefit Package (BBP) for patients to benefit from both public and private health 
care providers contracted with SSI. Patients are obliged to pay certain level co-
pays for extra services as defined in the regulation. Besides GHIS, patients could 
benefit from private health insurances(PHI) by paying relatively high level of pre-
miums for different types of PHI packages. Supplementary Health Insurance(SHI) 
law has been enacted in June 2012 and patients started to benefit from SHI by 
paying relatively lower premiums for health care services that are not covered 
or partially covered by BBP. The objective is to evaluate the significance and 
potential of SHI in Turkey. Methods: Regulations of SSI, OECD publications, 
International Investors Association’s Turkey Report and database of Insurance 
Association of Turkey are examined. Results: Number of private hospitals has 
increased by 50% over 5 years and reached out 500 by 2012. Parallel with this 
growth, PHI sector market share has also increased. By 2012, number of people 
covered by PHI has reached out more than 2 million and the PHI market is 
expected to reach nearly USD 2 billion in 2015. Meanwhile, approximately 20 
thousand people has covered by SHI since November 2012 and SHI is expected to 
reach 5 million people next 5 years. ConClusions: Public health care expendi-
ture is continuously rising due to increased health demand, increased coverage 
and demographic changes. In order to assure a financially sustainable health 
care system, PHI could be an option and create source of funding for the health 
care expenditure. In this context, SHI will reduce the pressure on public health 
budget, create an area of growth for the private health insurance sector, allowing 
health care providers supplying both public and private health care to become 
more effective.
